Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

Cold Spring Harbor Molecular Case Studies is a prestigious journal published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, that has garnered considerable attention in the fields of Biochemistry, Genetics, and Molecular Medicine. With a focus on the intersection of molecular biology and clinical case studies, this journal serves as a key resource for researchers and practitioners seeking to explore novel insights into genetic disorders and biomedical advances. Its impact is underscored by its categorization in Q2 in various disciplines in 2023, reflecting its significance and influence within the academic community. Although currently not labeled as Open Access, Cold Spring Harbor Molecular Case Studies provides a rigorous platform for disseminating high-quality, peer-reviewed research that drives innovation and enhances understanding in these rapidly evolving fields. As a supporter of advancing scientific knowledge, this journal is essential for those dedicated to the exploration of molecular mechanisms and their clinical implications.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

Application of Clinical Genetics is a premier open-access journal published by Dove Medical Press Ltd., dedicated to advancing the field of clinical genetics since its inception in 2008. Based in New Zealand, this journal has established itself as a significant resource for researchers, clinicians, and students alike, contributing to the body of knowledge in both genetic medicine and clinical applications. With an impact factor reflecting its contributions to the field, the journal holds positions in the Q2 and Q3 quartiles of the 2023 Genetics categories, showcasing its relevance and scientific merit. Furthermore, it ranks #43 out of 99 in Clinical Genetics and #153 out of 347 in Biochemistry, Genetics, and Molecular Biology, indicating robust performance amongst its peers. The journal’s broad scope, encompassing various aspects of clinical genetics, ensures that it remains at the forefront of critical discussions, innovative research, and applications essential for the progression of personalized medicine. Researchers and professionals are encouraged to explore its openly accessible content that fosters collaboration and the sharing of knowledge in this dynamic and rapidly evolving field.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Familial Cancer is a premier journal dedicated to advancing the understanding of hereditary cancer, published by Springer. With an ISSN of 1389-9600 and E-ISSN 1573-7292, this journal serves as an essential platform for researchers and clinicians focused on the genetic predispositions to cancer and the implications for patient care. Since its inception in 2001, Familial Cancer has built a strong reputation, being consistently ranked in the Q2 category across several key research areas including Cancer Research, Genetics, and Oncology. As of 2023, it holds significant Scopus rankings, reflecting its impactful contributions in the fields of Medicine and Genetics, with a focus on clinical applications. The journal does not currently offer Open Access, emphasizing the commitment to rigorous peer review and high-quality publications. It is vital for emerging researchers and seasoned professionals alike, providing insights into the hereditary aspects of cancer and fostering developments that can lead to better prevention and therapeutic strategies.

The JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, published by Walter de Gruyter GmbH, is a reputable peer-reviewed journal dedicated to advancing the field of pediatric endocrinology and metabolism. Since its inception in 1985, this journal has become a vital resource for professionals and researchers, providing insights into the latest advancements, clinical practices, and foundational research in the care of children with endocrine disorders. With a noted Q3 ranking in Endocrinology, Diabetes and Metabolism, and a robust focus on Pediatrics, Perinatology, and Child Health, it addresses important topics such as hormonal imbalances and metabolic syndromes in young populations. Despite its non-open access status, it continues to play an essential role in bridging the knowledge gap within our understanding of children's health and disease, contributing significantly to the progress in this specialized field.

JOURNAL OF MEDICAL GENETICS, published by the BMJ PUBLISHING GROUP, stands as a premier platform in the field of genetics, focusing on both fundamental genetic research and its clinical applications. With a distinctive legacy dating back to 1965 and a significant role in advancing the understanding of genetic disorders, this journal has established itself in the top tiers with a commendable Q1 category ranking in both Genetics and Clinical Genetics as of 2023. The journal's impact is underscored by its Scopus rankings, placing it among the leading journals in the fields of medicine and genetics. Researchers and practitioners are drawn to its rigorous peer-review process and its commitment to disseminating high-quality research findings, critical reviews, and innovative clinical practices. While it is not an open-access journal, the insights provided are invaluable for anyone looking to deepen their knowledge or contribute to the burgeoning field of medical genetics.

AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS is a premier peer-reviewed journal published by Wiley, focusing on the intricate and evolving field of medical genetics. With its ISSN 1552-4868 and E-ISSN 1552-4876, the journal has established itself as a significant resource for researchers, professionals, and students alike, addressing cutting-edge developments in genetic research and clinical practice. Ranked in the top quartile (Q2) in both Genetics and clinical Genetics categories for 2023, it maintains an impressive Scopus ranking, positioning it within the 75th and 71st percentiles for Medicine and Genetics respectively. The journal encourages open access to its content, promoting wider dissemination of knowledge and fostering collaboration among medical genetics experts. From its inaugural issues in 1980 to its ongoing publications, the journal aims to bridge the gap between genetics research and its clinical applications, providing insights that reflect the latest advancements in the field. As it continues to serve the global medical community, the AMERICAN JOURNAL OF MEDICAL GENETICS PART C remains a vital source for those seeking to understand the complexities of genetic disorders and their implications for health and disease.

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.